Table 3.
Clinical outcomes in patients receiving at least second-line therapy for adv/met ESCC
| All ≥ 2L patients (n = 86) | 2L taxane therapy (n = 37) | 2L non-taxane therapy (n = 49) | |
|---|---|---|---|
| Median (range) follow-up from start of 2L, months | 5.1 (0.03–74.0) | 6.0 (0.03–74.0) | 4.4 (0.1–47.4) |
| Deaths, n (%) | 63 (73.3) | 26 (70.3) | 37 (75.5) |
| Median (95% CI) OS from start of 2L, months | 6.7 (5.1–8.3) | 7.3 (5.9–11.5) | 5.1 (2.9–7.6) |
| 12-month (SE) survival | 28.4 (5.5) | 29.3 (8.6) | 28.0 (7.2) |
| 24-month (SE) survival | 19.5 (5.0) | 18.3 (7.3) | 21.0 (6.9) |
| Median (95% CI) DoT, months | 2.6 (2.1–3.7) | 2.1 (1.8–3.0) | 3.3 (2.6–6.7) |
Adv/met unresectable locally advanced, recurrent or metastatic, CI confidence interval, DoT duration of therapy, ESCC esophageal squamous cell carcinoma, SE standard error